aus dem amerikanischen Board:
REASONS WE ARE GOING HIGHER: Great info by akmersil
1.
Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF) is currently one of the most potent factors protecting and rescuing neurons in pre-clinical models of Parkinson’s disease. We found a cell-penetrating octapeptide from MANF that protects the cultured dopaminergic neurons from apoptotic death. The small size and cell-penetrating properties makes this peptide an attractive candidate for therapy in Parkinson’s disease as it spreads in the brain better than the larger full-length MANF and gets inside the neurons.
2.
SUNNYVALE, Calif., Nov. 1, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it intends to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA). The strategy is centred on exploiting MANF's unique mechanism of action related to facilitating proper protein folding and processing in the endoplasmic reticulum in order to identify rare and/or ultra-rare diseases where MANF treatment may play a significant role in improving patient outcomes in disease states where no other treatment options are currently available.
3.
SUNNYVALE, Calif., Oct. 25, 2012 -- /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
4.
SUNNYVALE, Calif., Sept. 26, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented anti-apoptotic therapeutic protein MANF, today announced the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled " Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls.
5.
"The generation of positive ischemia/reperfusion in-vivo animal data in a model of myocardial infarction represents a significant scientific milestone for MANF as scientifists look to establish the therapeutic profile of MANF in ischemic heart disease," said Gerald E. Commissiong, President & CEO of Amarantus. "As the research on MANF moves forward around the globe, Amarantus will leverage the data generated by collaborators and independent researchers to improve the value of our IP portfolio as well as overall shareholder value."
Since 2011, the Company has reported positive data in pre-clinical models of Parkinson's disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson's disease.
6. there is more. But this alone, shows significant excitement, and positive reasoning this stock price should do well going forward!
Re: Reasons Why we are going Higher
By akmersil.Nov 3, 2012 1:14 PM.Permalink
.
1. AMBS acquired an exclusive option to license the LymPro Alzheimer's Diagnostic Blood Test from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, LLC
2. AMBS had Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;
3. AMBS Secured the license for the NuroPro Parkinson's diagnostic blood test;
4. AMBS Successfully concluded its research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury.
5. AMBS anticipates announcing interim results from on-going delivery experiments by the end of October.
6. AMBS has a Parkinson’s disease program, comprised of an early detection diagnostic blood test and a disease-modifying protein drug candidate. AMBS owns the rights to a potential cure for Parkinson’s—a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis. That program is currently funded by a research grant from the Michael J. Fox Foundation for Parkinson’s research...
7. AMBS also owns the license to a groundbreaking diagnostic platform called NuroPro for Parkinson’s that allows neurologists to accurately diagnose and track the progression of Parkinson’s disease in patients. The Companies believe that Amarantus’ NuroPro test for Parkinson’s disease could be on market in certain regions as early as 2013.
8. Over $30MM has already been invested in the research and development of AMBS product candidates from biopharmaceutical companies, non-profit organizations, academic researchers and government agencies, including the National Institutes of Health.
9. According to a2011 report by Visiongain, the market for Parkinson's disease drugs could grow to a value of $3.75BB by 2015; AMBS is working on a candidate in the disease-modifying drug class which, if successful, could grab significant market share as well as substantially grow the overall Parkinson’s drug market. There are currently no diagnostic tests available for Parkinson’s disease, thus making AMBS test a first of its kind product capable of gaining a market leading position.
10. AMBS announced Drug Test Results & the publication of positive, peer-reviewed efficacy data for MANF in an animal model of myocardial infarction. The results were published in The Journal of Biological Chemistry (JBC) by the Glembotski Lab at the San Diego State University's (SDSU) Department of Biology and the SDSU Heart Institute. The research paper entitled "Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion" reports a ~44% reduction in infarct zone size in MANF-treated mice when compared with controls
.
5users liked this posts1users disliked this posts
Reply
Ignore User
|
Report Abuse
..
Re: Re: Reasons Why we are going Higher
By akmersil.Nov 3, 2012 1:20 PM.Permalink
.
With cases of Parkinson’s disease sharply on the rise as the world’s population ages, the costs associated with the illness are rapidly rising, too. Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC) is working on new solutions to help reduce the global costs associated with Parkinson’s and other neurological diseases.
Experts estimate that up to 10 million people worldwide are currently living with Parkinson’s, including as many as one million Americans. An average of 60,000 Americans are diagnosed with the disease each year, but that number doesn’t include thousands of cases that go undetected or undiagnosed.
What’s worse, the numbers are growing.
There is reason for hope, however. RBCC is currently negotiating a definitive agreement with Amarantus Biosciences (AMBS), a company that could be on the verge of revolutionary new diagnostic and therapeutic tools for Parkinson’s patients and their doctors.
RBCC is working to deliver breakthroughs like these to the people who need them most. The market for Parkinson’s drugs could grow to a value of $3.75 billion by 2015, according to a report last year by Visiongain.
Sentiment: Strong Buy
.
3users liked this posts1users disliked this posts
Reply
Ignore User
|
Report Abuse
..View Replies.
Re: Reasons Why we are going Higher
By akmersil.Nov 3, 2012 10:06 PM.Permalink
.
Form 8-K for AMARANTUS BIOSCIENCES, INC.
--------------------------------------------------
31-Oct-2012
Other Events
Item 8.01. Other Events
On October 26, 2012, Amarantus BioSciences, Inc. issued a Convertible Promissory Note to Dr. Joseph Rubinfeld, co-founder of Amgen, in the principal amount of $10,000.00 The Note bears interest at the rate of six percent (6%) per annum until paid in full and is convertible into shares of Amarantus common stock at the price of $0.01 per share upon ten (10) days written notice to Amarantus. Dr. Joseph Rubinfeld has submitted a conversion notice to convert his entire note into common stock, for a total 1,000,000 common shares, to be issued within 10 days.
The principal amount of the Note is not material to Amarantus and if converted, the number of shares issued in conversion would be less that one percent (1%) of the outstanding shares of Amarantus
.
1users liked this posts0users disliked this posts
Reply
Ignore User
|
Report Abuse
..
Re: Re: Reasons Why we are going Higher
By akmersil.Nov 4, 2012 12:13 PM.Permalink
.
Sept. 24, 2012 –/PRNewswire/ — Amarantus BioSciences, Inc.
“Treatment with MANF prior to inducing PD-like conditions in animals protected the subjects from the onset of neuron degeneration. Even more impressively, in animals where Parkinson`s was already present, treatment with MANF provided restorative benefits that included regaining motor function, as well as the maintenance and increase in function of the neurons that were still present. Cumulatively, these studies provide strong evidence that MANF has the potential to serve as a first-in-class curative treatment for degenerative neurological disorders that include PD. Amarantus is currently in the design and development stages to move MANF into clinical trials.” The report also states: “Amarantus owns the license for Power3 Medical Products` NuroPro Blood Test as it relates to Parkinson`s disease. NuroPro is a diagnostic platform for the early detection of neurodegenerative diseases. The PD application of this diagnostic has completed proof-of-concept and Phase I clinical validation studies
Sentiment: Strong Buy
|
1 |
|
3 |
4 |
5 |
6
| 6
Thread abonnieren
